Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Key market highlights • Biopsy • Liquid biopsy: Future of cancer diagnostics PART 05: Market landscape • Market overview • Clinical trials • Market size and forecast • Five forces analysis PART 06: Market segmentation by product • CTCs and ctDNA • Exosomes and RNA PART 07: Market segmentation by end-user • Global liquid biopsy market by end-user in 2016 • Hospitals • Clinical diagnostic laboratories • Physicians' office laboratories PART 08: Geographical segmentation • Liquid biopsy market in Americas • Liquid biopsy market in US • Liquid biopsy market in EMEA • Liquid biopsy market in UK • Liquid biopsy market in APAC • Liquid biopsy market in China PART 09: Market drivers • Increasing prevalence of cancer cases in older population • Government initiatives and pilot programs • Collaboration between companies for co-development of products PART 10: Impact of drivers PART 11: Market challenges • Lack of reimbursement • Dearth of skilled professionals, laboratory technicians, and oncologists • High cost of clinical trials and failure rate in clinical trials PART 12: Impact of drivers and challenges PART 13: Market trends • Focus on chip development as novel product • Venture capitals for market entry of start-ups • Direct-to-consumer laboratory testing PART 14: Vendor landscape • Competitive landscape PART 15: Key vendor analysis • Biocept • Exosome Diagnostics • QIAGEN • Roche Molecular Diagnostics • Key companies to watch • Other prominent vendors PART 16: Appendix • List of abbreviations   List of Exhibits Exhibit 01: Comparison: Liquid biopsy and tissue biopsy methods Exhibit 02: Types of liquid biopsy tests Exhibit 03: Market overview: Global liquid biopsy market Exhibit 04: Pipeline of liquid biopsy in Americas Exhibit 05: Pipeline of liquid biopsy in Europe Exhibit 06: Pipeline of liquid biopsy in APAC Exhibit 07: Global liquid biopsy market 2016-2021 ($ millions) Exhibit 08: Global liquid biopsy potential market 2016 Exhibit 09: Market scenario: Market impact analysis of global liquid biopsy market ($ millions) Exhibit 10: Five forces analysis Exhibit 11: Global liquid biopsy market segmentation by product 2016 Exhibit 12: Market overview: CTCs and ctDNA Exhibit 13: Market overview: Exosomes and RNA Exhibit 14: Revenue generated by diagnostic and medical laboratories in US 2009-2014 ($ millions) Exhibit 15: Global liquid biopsy market by geography 2016 and 2021 Exhibit 16: Market overview: Liquid biopsy market in Americas Exhibit 17: New cancer cases and cancer deaths in US 2015-2020 (per 100,000 population) Exhibit 18: Global liquid biopsy market in Americas 2016-2021 ($ millions) Exhibit 19: Market impact analysis: Liquid biopsy market in Americas Exhibit 20: Market overview: Liquid biopsy market in US Exhibit 21: Market overview: Liquid biopsy market in EMEA Exhibit 22: Global liquid biopsy market in EMEA 2016-2021 ($ millions) Exhibit 23: Market impact analysis: Liquid biopsy market in EMEA Exhibit 24: Market overview: Liquid biopsy market in UK Exhibit 25: Market overview: Liquid biopsy market in APAC Exhibit 26: Colorectal cancer mortality per 100,000 individuals in APAC 2003 and 2013 Exhibit 27: Global liquid biopsy market in APAC 2016-2021 ($ millions) Exhibit 28: Market impact analysis: Liquid biopsy market in APAC Exhibit 29: Market overview: Liquid biopsy market in China Exhibit 30: Older population with cancer in US Exhibit 31: Government initiatives for cancer and liquid biopsy testing in some countries Exhibit 32: Market impact analysis: Collaboration between medical device and pharmaceutical companies for liquid biopsy Exhibit 33: Impact of drivers Exhibit 34: Number of skilled physicians per 1,000 population 2014 Exhibit 35: Impact of drivers and challenges Exhibit 36: Market impact analysis: Focus on novel product development by institutes and companies Exhibit 37: Collaboration of companies with venture capitalists Exhibit 38: Competitive structure analysis of global liquid biopsy market 2016 Exhibit 39: Competitive landscape analysis of global liquid biopsy market 2016 Exhibit 40: Strategic recommendation for vendors in the global liquid biopsy market Exhibit 41: Biocept: Key highlights Exhibit 42: Biocept: Strength assessment Exhibit 43: Biocept: Strategy assessment Exhibit 44: Biocept: Opportunity assessment Exhibit 45: Exosome Diagnostics: Key highlights Exhibit 46: Exosome Diagnostics: Strength assessment Exhibit 47: Exosome Diagnostics: Strategy assessment Exhibit 48: Exosome Diagnostics: Opportunity assessment Exhibit 49: QIAGEN: Key highlights Exhibit 50: QIAGEN: Strength assessment Exhibit 51: QIAGEN: Strategy assessment Exhibit 52: QIAGEN: Opportunity assessment Exhibit 53: Roche Molecular Diagnostics: Key highlights Exhibit 54: Roche Molecular Diagnostics: Strength assessment Exhibit 55: Roche Molecular Diagnostics: Strategy assessment Exhibit 56: Roche Molecular Diagnostics: Opportunity assessment Exhibit 57: Key companies: Global liquid biopsy market

Biocept, Exosome Diagnostics, QIAGEN, Roche Molecular Diagnostics, AccuraGen, Agena Bioscience, Bio-Rad Laboratories, CellMax Life, Chronix Biomedical, Clearbridge BioMedics, Circulogene Theranostics, Cynvenio Biosystems, Epic Sciences, Freenome, Genomic Health, Natera, Novogene, OncoCyte, Pathway Genomics, Personal Genome Diagnostics, RainDance Technologies, Sequenom, Sysmex, Thermo Fisher Scientific, Transgenomic, Vermillion, and WaveSense